AC Immune (ACIU)
(Delayed Data from NSDQ)
$2.12 USD
-0.04 (-1.85%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.12 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACIU 2.12 -0.04(-1.85%)
Will ACIU be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACIU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACIU
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
ACIU: What are Zacks experts saying now?
Zacks Private Portfolio Services
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know
Other News for ACIU
AC Immune SA Announces AGM Results and Strategic Approvals
AC Immune SA Announces Leadership Changes in Development Team
AC Immune SA Announces Board Changes Ahead of June 2025 AGM
AC Immune’s Promising Pipeline and Strong Financial Position Justify Buy Rating
Analysts’ Top Healthcare Picks: AC Immune SA (ACIU), Praxis Precision Medicines (PRAX)